Scarica l'app Stockscreener
0.4135
0.95%
-0.0169
Precedente Chiudi:
$0.4304
Aprire:
$0.447
Volume 24 ore:
58,298
Relative Volume:
0.02
Capitalizzazione di mercato:
$4.21M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+6.57%
1M Prestazione:
-28.11%
6M Prestazione:
-99.41%
1 anno Prestazione:
-99.88%
Intervallo 1D:
$0.41
$0.447
Intervallo di 1 settimana:
$0.3795
$0.4797
Portata 52W:
$0.375
$402.48
AEON Biopharma Inc. Stock (AEON) Company Profile
Nome
AEON Biopharma Inc.
Settore
Industria
Telefono
(949) 354-6499
Indirizzo
5 Park Plaza, Suite 1750, Irvine
Confronta AEON con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.4263 | 4.21M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
494.78 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
612.43 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
615.20 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.41 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
251.10 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-18 | Iniziato | H.C. Wainwright | Buy |
AEON Biopharma Inc. Borsa (AEON) Ultime notizie
AEON Biopharma gets NYSE American nod for compliance plan - Investing.com
AEON Biopharma gets NYSE American nod for compliance plan By Investing.com - Investing.com India
AEON Biopharma Says NYSE American Accepts Plan to Regain Compliance - marketscreener.com
AEON Biopharma Receives Acceptance from NYSE American to Regain Compliance with Listing Standards - Nasdaq
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - The Manila Times
NYSE American Grants AEON Biopharma 2-Year Lifeline to Meet Listing Requirements - Stock Titan
What was AEON Biopharma Inc (AEON)’s performance in the last session? - uspostnews.com
Analyzing the Impact of Earnings Reports on AEON Biopharma Inc Inc. (AEON) Price Performance - investchronicle.com
Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance - insights.citeline.com
AEON Biopharma, Inc. Announces Executive Changes, Effective as of April 4, 2025 - marketscreener.com
AEON Biopharma announces CEO appointment - MSN
AEON Biopharma names Rob Bancroft as new CEO By Investing.com - Investing.com South Africa
Aeon Biopharma Names Robert Bancroft CEO - marketscreener.com
AEON Biopharma Appoints New CEO Robert Bancroft - TipRanks
Aeon Biopharma (AEON) Appoints Rob Bancroft as New CEO | AEON Stock News - GuruFocus
AEON Biopharma Appoints Rob Bancroft as CEO - MarketWatch
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer - The Manila Times
AEON Biopharma names Rob Bancroft as new CEO - Investing.com
AEON Biopharma Appoints New CEO Rob Bancroft: Inside the $1M+ Executive Compensation Deal - Stock Titan
Former Revance Therapeutics Leader Takes AEON Helm: Inside the Race to Challenge BOTOX's $3B Market - Stock Titan
AEON Biopharma (NASDAQ:AEON) Trading 2.5% Higher – Time to Buy? - Defense World
AEON Biopharma announces new interim CEO and CFO By Investing.com - Investing.com Australia
AEON Biopharma Appoints Jost Fischer as Interim CEO - TipRanks
AEON Biopharma announces new interim CEO and CFO - Investing.com
Trading Day Triumph: AEON Biopharma Inc (AEON) Ends at 0.42, a -10.60 Surge/Plunge - DWinneX
Aesthetic Medicine Powerhouse: BOTOX Veteran Takes Helm at Jeune Aesthetics - Stock Titan
AEON Biopharma Inc (AEON) Stock: The Story of a 52-Week Stock Range - investchronicle.com
AEON Biopharma’s Strategic Progress and Financial Turnaround - TipRanks
Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1 - NewsBreak: Local News & Alerts
AEON Biopharma announces leadership change amid growth strategy By Investing.com - Investing.com Philippines
Aeon Biopharma CEO to Step Down Next Week - Orange County Business Journal
AEON Biopharma Announces CEO Transition - The Manila Times
AEON Biopharma CEO Marc Forth to Resign; Board Chairman Jost Fischer Is Interim CEO - MarketScreener
AEON Biopharma announces leadership change amid growth strategy - Investing.com
AEON Biopharma Announces CEO Resignation and Interim Appointment - TipRanks
Leadership Shift at AEON Biopharma: CEO Exit Won't Delay Critical FDA Timeline - Stock Titan
AEON Eyeing FDA Meeting On Botox Biosimilar By The End Of 2025 - insights.citeline.com
AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
AEON Biopharma, Inc. Advances Biosimilar Development for ABP-450 with FDA Meeting Planned for 2025 - Nasdaq
AEON's $20M Cash Injection Powers Game-Changing BOTOX Alternative Development - Stock Titan
AEON Biopharma (NASDAQ:AEON) Stock Price Down 7.6% – Should You Sell? - Defense World
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Understanding AEON’s financial ratios: A beginner’s guide - US Post News
AEON Biopharma Releases New Corporate Presentation - TipRanks
AEON Biopharma : Corporate Presentation -March 10, 2025 at 06:26 am EDT - Marketscreener.com
AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference - The Manila Times
AEON CEO to Showcase Botulinum Toxin Pipeline at Major Healthcare Conference - StockTitan
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable
Cervical Dystonia Market Expected to Experience Major Growth - openPR
AEON stock touches 52-week low at $0.76 amid market shifts - Investing.com
AEON Biopharma Inc. Azioni (AEON) Dati Finanziari
Non sono disponibili dati finanziari per AEON Biopharma Inc. (AEON). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.63%
Capitalizzazione:
|
Volume (24 ore):